Updated Statement: Bristol Myers Squibb on Coronavirus (COVID-19)

08/04/2020

Throughout the unprecedented and evolving COVID-19 pandemic, Bristol Myers Squibb has focused on protecting the health and safety of our workforce, ensuring the continued supply of our medicines to our patients and supporting relief efforts across the globe.

Workplace and Community

  • Our efforts to bring our remote workforce back to our 250+ sites around the world and into the field are being guided by the following principles:
  • Serving the Needs of our Patients and Customers
  • Prioritizing Health and Safety
  • Following Medical Advice and Government Direction
  • Leading with Compassion and Flexibility
  • Modeling Key Learnings
  • No single approach fits for every site or market. While timelines and circumstances vary across the globe, across our enterprise, we are taking a thoughtful and phased approach.  
  • We continue to take significant measures to protect the safety of our colleagues on site, including providing protective equipment, ensuring physical distancing and enhancing cleaning.

Supply of Our Medicines

  • An important element of keeping our promise to patients, their families and our healthcare providers is to ensure that our supply chain continues to deliver our medicines without interruption. 
  • Our clinical and commercial supply chain teams have proactively booked alternative means for moving our raw materials and products to our markets and clinical sites over the past months. Thanks to these efforts, we have not seen any disruption in our clinical or commercial supply chain due to the pandemic.

Our Clinical Trials and Research

  • We are working with health authorities and investigators to protect our trial participants and personnel at Bristol Myers Squibb and our clinical trial sites, while ensuring regulatory compliance and the integrity of our science.
  • We have provided clinical trial investigators with updated guidance regarding the conduct of BMS clinical trials worldwide in light of COVID-19, and are taking into account guidance from health authorities, where applicable.

Contributions to Research, Life-Sciences Industry

  • We are participating in several cross-industry groups and public-private partnerships designed to foster collaboration and coordinate industry response efforts, and thereby accelerate the development, manufacturing, and delivery of vaccines, diagnostics, and treatments for COVID-19.
  • Bristol Myers Squibb has a proof-of-concept clinical trial in progress to assess the safety and efficacy of ORENCIA® (abatacept) in hospitalized patients with COVID-19 due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 
  • We are also evaluating certain compounds in our portfolio that could be included in near-term clinical trials with a focus on agents that may have an impact on the inflammatory immune response associated with COVID-19. This research may advance as either company-sponsored or investigator-sponsored trials under the leadership of a cross-functional team focused on advancing this science with a sense of urgency. 
  • Our contributions to COVID-19 research reflect collaborative and productive discussions internally and with the broader life sciences community about how we can have the greatest impact given our company’s areas of strength, and we will continue to engage in this way in order to support the significant and rapid effort underway as the science evolves.

Global Relief Efforts

  • Bristol Myers Squibb and the Bristol Myers Squibb Foundation, a 501(c)(3) organization, are actively and separately contributing to relief efforts around the world. Together, Bristol Myers Squibb and the Bristol Myers Squibb Foundation have contributed more than $31 million in financial support and needed products (e.g., PPE and medical equipment) to relief efforts in 43 countries. Both the company and the Foundation are focusing on areas of highest unmet need, including providing for basic human needs, addressing medical supply shortages and supporting continued care in the most vulnerable communities.
  • The Bristol Myers Squibb Foundation has supported nearly 50 organizations in the U.S. and more than 150 organizations globally that care for patients and that support those on the frontlines of the COVID-19 response. In addition, it has contributed funding to support the work of more than 40 patient advocacy groups and professional societies. Also, to support research, education, and a wide range of efforts to benefit patients in need, Bristol Myers Squibb is engaging with more than 250 patient and professional organizations. 

Notable examples include:

  • A $12 million grant from the Bristol Myers Squibb Foundation to Team Rubicon’s and Patient Advocate Foundation’s COVID-19 Emergency Food Assistance Program, which is providing assistance to immunocompromised patients living with cancer, multiple sclerosis or rheumatoid arthritis whose ability to access or afford food and other nutritional needs is at risk due to the COVID-19 pandemic.
  • A program with the U.S. Department of Veterans Affairs (VA) to deliver cutting-edge cancer care to veterans through Teleoncology hubs for which the Bristol Myers Squibb Foundation committed to provide the VA with a grant totaling $4.5 million over three years.
  • Bristol Myers Squibb’s partnership with GRYT Health to launch the COVID Advocacy Exchange, a virtual platform to unite patient advocacy organizations, patients, policy makers, healthcare practitioners and industry in the exchange of information.
  • A $500,000 grant supporting Project ECHO to scale healthcare provider training and deepen the effectiveness of the implementation of COVID-19 clinical care, public health, health service delivery and community outreach and engagement interventions for communities and populations most at risk from the virus.
  • 20 Seconds or More/20 Segundos o Mas, a PSA campaign to encourage hand washing and other safety protocols among youth, funded by the Bristol Myers Squibb Foundation and Bristol Myers Squibb employee resource groups Black Organization for Leadership Development and Organization for Latino Achievement.

We are proud of our colleagues around the world, who mobilized to help our communities and industry respond to the COVID-19 crisis. Our colleagues who are licensed healthcare professionals are being supported as they volunteer in local hospitals and are continuing to receive pay. Our colleagues across the world also have volunteered virtually. Through Skills2Give, an ongoing Bristol Myers Squibb volunteer program, colleagues in the U.S., U.K. and Australia have the option to select from virtual volunteer opportunities with thousands of nonprofit organizations. Over 3,700 employees are registered with the program. 

We are grateful to the healthcare professionals on the frontlines who are fighting to help patients with COVID-19. We are thankful to our more than 30,000 colleagues who have never stopped working for patients, have demonstrated incredible resolve and support for one another, and have contributed meaningfully to global relief efforts.

As a responsible global citizen, we will take all necessary actions to promote public health and carry out our mission of providing life-saving medicines to the patients who depend on us.

For further inquiries, please contact media@bms.com.

Multimedia Files:

Categories: Press Releases